Hybio Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Hybio Pharmaceutical has a total shareholder equity of CN¥780.0M and total debt of CN¥1.8B, which brings its debt-to-equity ratio to 228.8%. Its total assets and total liabilities are CN¥3.0B and CN¥2.2B respectively.
Key information
228.8%
Debt to equity ratio
CN¥1.78b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥73.83m |
| Equity | CN¥779.98m |
| Total liabilities | CN¥2.25b |
| Total assets | CN¥3.03b |
Recent financial health updates
Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt
Jul 20
Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?
Feb 26Recent updates
Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt
Jul 20Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues
Jun 03Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up
Feb 29Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?
Feb 26Financial Position Analysis
Short Term Liabilities: 300199's short term assets (CN¥452.4M) do not cover its short term liabilities (CN¥1.1B).
Long Term Liabilities: 300199's short term assets (CN¥452.4M) do not cover its long term liabilities (CN¥1.2B).
Debt to Equity History and Analysis
Debt Level: 300199's net debt to equity ratio (219.4%) is considered high.
Reducing Debt: 300199's debt to equity ratio has increased from 68.1% to 228.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 300199 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 300199 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 20.9% per year.